Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. Both have FDA-approved products for chronic weight management, but they differ in mechanism, product labeling, doses, clinical evidence and individual response. Neither should be chosen solely from headline weight-loss percentages.
This article is for general educational information and is not a substitute for diagnosis, prescribing, dosing or individualized medical advice. Semaglutide is a prescription medicine. Product indications and instructions differ by formulation. Readers should use the exact current prescribing information and speak with a licensed healthcare professional. |
The main mechanism difference
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. That is the clearest pharmacologic difference and the reason tirzepatide is often described as a dual agonist.
Both can affect appetite and calorie intake, but their molecules and clinical programs are not the same.
Approved weight-management products
Wegovy contains semaglutide and Zepbound contains tirzepatide. Each has product-specific FDA labeling, dose escalation, contraindications, warnings and indications.
Do not compare a diabetes-labeled product with a weight-management-labeled product as if the names were interchangeable.
Side effects overlap
Both medicines commonly cause gastrointestinal effects such as nausea, diarrhea, vomiting and constipation. Each also carries important warnings and contraindications that must be reviewed in the current label.
Tolerance can differ between individuals, so a medicine that looks stronger in an average trial result may not be the better personal choice.
Why trial percentages do not answer “which is better for me?”
Clinical trials differ in design, population, duration, dose and comparator. Cross-trial comparisons can be misleading. Headline averages also hide wide individual variation.
A clinician considers health conditions, other medicines, prior treatment, side effects, coverage, availability and patient preference.
Switching is not a DIY decision
There is no simple milligram conversion between semaglutide and tirzepatide. Switching requires a prescriber to choose timing and a new escalation plan based on the exact products and patient situation.
Frequently Asked Questions
Is tirzepatide a GLP-1?
Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors.
Are Wegovy and Zepbound the same medication?
No. Wegovy contains semaglutide; Zepbound contains tirzepatide.
Which causes more weight loss?
Clinical studies report different averages, but personal choice should not be based on a simple cross-trial comparison.
Can I switch from semaglutide to tirzepatide?
A switch may be considered clinically, but timing and dosing should be directed by a prescriber.
